Targeting Drugs with a Special Polysarcosine Polymer Chain
This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.
Original patent title: “Ligand-drug-conjugate comprising a single molecular weight polysarcosine”
This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight. Owned by Mablink Bioscience SAS with 21 claims, and it is expected to expire in 2044.
Coverage
What does this patent actually cover?
This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.
The gap
What does this patent NOT cover?
- Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover LDCs where the polymer is not a 'homopolymer' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1), meaning it would not cover conjugates made with copolymers or other polymer types.
- Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 2).
- Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Antibody-drug conjugates (ADCs) in cancer therapy
Targeted drug delivery systems for chemotherapy
Biologics with enhanced half-life or reduced immunogenicity
Polysarcosine-based drug carriers
Why it matters
The bigger picture
Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.
Filed
September 24, 2024
Market context
Who's building on this
Companies in this space
Mablink Bioscience SAS, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is actively developing next-generation antibody-drug conjugates using polysarcosine-based linkers. Other major pharmaceutical companies and biotech firms focused on targeted drug delivery, such as Seagen (now part of Pfizer), Genentech (Roche), and AstraZeneca, are also heavily invested in advancing LDC technology, continually seeking improved linker and polymer chemistries.
Market impact
This patent contributes to the rapidly evolving field of targeted drug delivery, particularly for cancer therapies. By proposing a more precise polymer component, it could enable the development of LDCs with improved therapeutic windows, meaning better efficacy with fewer side effects. This could lead to new drug candidates that are more stable and predictable, potentially expanding the market for highly potent, targeted medicines and offering new treatment options for patients.
Claim 1 — Plain English
What this patent covers
This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (Claim 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.
The clever bit
The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.
What it does not cover
- Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).
- Does not cover LDCs where the polymer is not a 'homopolymer' (Claim 1), meaning it would not cover conjugates made with copolymers or other polymer types.
- Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (Claim 2).
- Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (Claim 1).
- Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (Claim 1).
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Limited data
Citation count
0/40
No citations yet
Claim breadth
14/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
0/20
Older than 20 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$59K – $187K
Midpoint $117K · 17.8 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
21 claims as filed with the patent office.
Concepts involved
Cite this patent
VIRICEL, W. Targeting Drugs with a Special Polysarcosine Polymer Chain (U.S. Patent No. 20,250,057,964). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20250057964/ligand-drug-conjugate-comprising-a-single-molecular-weight-polysarcosine
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20250057964"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 9884123 · 2018 · INVICTUS ONCOLOGY PVT
Targeted Platinum Drugs for Cancer Treatment
US 20210301031 · Mersana Therapeutics
Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds
US 12121527 · 2024 · NBE Therapeutics AG
Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment
US 10772965 · 2020 · Rc Biotechnologies
A Chemical Linker for Attaching Drugs to Antibodies
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Targeting Drugs with a Special Polysarcosine Polymer Chain cover?
This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.
Who owns patent US 20250057964?
This patent is owned by Mablink Bioscience SAS.
When does this patent expire?
This patent is expected to expire on September 24, 2044, when the invention enters the public domain.
What problem does this patent solve?
Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.
What does this patent NOT cover?
Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).
Patent monitoring






